Clinical Trials
4
3 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
Active, not recruiting
3
75.0%
Completed
1
25.0%
No approval data available
- Precipio (PRPO) combines clinical laboratory services with proprietary diagnostic product development, with pathology services focused primarily on hematologic cancers. - Biodesix (BDSX) provides blood-based diagnostic testing for lung disease, including tests that assess cancer risk in lung nodules and guide post-diagnosis treatment. - Biodesix has outperformed Precipio over the past three months (up 64.5% vs. 26.4%) and over the past year (up 150.9% vs. 112%). - Both stocks trade below the Zacks Medical sector average EV/S of 2.92X, with PRPO at 1.90X and BDSX at 2.89X.
- Precision medicine company Oncimmune Holdings has entered administration after failing to secure a buyer for its German subsidiary or raise additional capital to meet short-term funding needs. - The University of Nottingham spin-out has requested suspension of its shares on the AIM market, with trading halted as of March 17, 2025, following a 93% stock value decline over the past year. - Alvarez & Marsal Europe LLP managing directors will be appointed as administrators to preserve remaining business value for creditors, marking a significant setback for the autoantibody profiling services provider.
